BMJ2d
POS0894 ANTI-IL-6 THERAPY EFFECT FOR REFRACTORY JOINT AND SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS: A REAL-WORLD, SINGLE CENTER EXPERIENCE
Background: Emerging evidence during the last two decades supports a pivotal role of Interleukin 6 (IL-6) in the pathogenesis of Systemic Sclerosis (SSc). Standard immunosuppressive agents are often ...
BMJ3d
SAT0026 Survival and Mortality Rates in Lupus Nephritis Patients
Background Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease, characterized by multisystemic organ involvement and with a broad spectrum of clinical and laboratory manifestations.
BMJ3d
How to cope with pathogenic long-lived plasma cells in autoimmune diseases
Deutsches Rheumaforschungszentrum Berlin and Department of Rheumatology, Charité, Universitätsmedizin Berlin, Berlin, Germany Dr B F Hoyer, Deutsches Rheumaforschungszentrum Berlin and Department of ...
BMJ4d
POS1144 SERUM URIC ACID TO CREATININE RATIO IS ASSOCIATED WITH URINARY URIC ACID EXCRETION IN PATIENTS WITH GOUT
Background: Underexcretion of uric acid is the dominant mechanism leading to hyperuricemia [1] and the 24-hour urinary uric acid excretion is an important measurement. However, it is inconvenient due ...
BMJ6d
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Objectives To determine if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).
BMJ6d
Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis
Correspondence to Professor Annette van der Helm-van Mil, Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; A.H.M.van_der_Helm{at}lumc.nl Rheumatoid arthritis (RA) is ...
BMJ8d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ8d
POS0534 EFFICACY OF TELITACICEPT IN THE TREATMENT OF LUPUS NEPHRITIS: A 52-WEEK, MULTICENTER OBSERVATIONAL STUDY
1 University of Science and Technology of China, Rheumatology and Immunology, Hefei, China 2 Bengbu Medical University, Rheumatology and Immunology, Bengbu, China Background: The past decade has ...
BMJ9d
LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
11 University of Pennsylvania, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, PA, United States of America 12 University of Pennsylvania, Division ...
BMJ9d
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into ...
BMJ9d
AB0053 BERGENIN, ACTING AS AN AGONIST OF SIRT1, REDUCE SERUM URATE IN MICE THROUGH THE UPREGULATION OF ABCG2
Background: About 20% of individuals in the USA have asymptomatic hyperuricaemia [1]. However, Urate-lowering therapy in asymptomatic hyperuricaemia condition is still controversial considering the ...
BMJ10d
SP0168 Theory of poster design and presentation
This lecture introduces basic elements of poster design, and is followed after the session by a special poster tour devoted to design. It strongly links to the concepts discussed in my workshop on ...